Alpha-Lipoic Acid

Evidence-based overview of alpha-lipoic acid as a possible adjunct for peripheral neuropathy, including mechanisms, evidence limits, and safety notes

Alpha-lipoic acid, often shortened to ALA, is a small sulphur-containing compound used in neuropathy research and care discussions.

It is best understood as a nerve-supportive antioxidant and mitochondrial co-factor.

It is not a guaranteed fix.

It is also not the same thing as proven metal detox.

What it is

ALA has been used for years in Europe, especially in diabetic neuropathy care.

The main symptoms studied are burning, tingling, numbness, and nerve pain in the feet.

Within this documentation set, ALA is best framed as one possible tool inside a broader nerve-care plan.

That broader plan usually includes:

blood-sugar stability
nutrition and micronutrient support where needed
movement and safety work
sleep and nervous-system support

How it might help nerves

Several mechanisms are proposed.

Antioxidant support

ALA appears to reduce oxidative stress around nerves.

It may also help regenerate or support the body's own antioxidant systems, including glutathione, vitamin C, and vitamin E.

That matters because oxidative stress is one of the recurring themes in both diabetic and treatment-related nerve injury.

Mitochondrial support

ALA acts as a mitochondrial co-factor.

That means it may help nerve cells with energy production.

This is one reason it is discussed in neuropathy rather than only in glucose metabolism.

Microcirculation support

In diabetic neuropathy, ALA has been linked to improved microcirculation and nitric-oxide-mediated vasodilation.

That may help support blood flow to small nerve fibres.

Pain-signalling effects

Preclinical work suggests ALA may dampen inflammatory signalling and some pain-sensing pathways.

That could help explain why some people report less burning or shooting pain.

Where the evidence is strongest

The strongest human evidence is in painful diabetic neuropathy.

Repeated trials suggest ALA can improve symptom scores, especially for pain, tingling, and numbness.

The most commonly studied dose is 600 mg per day.

Some studies used intravenous ALA for 2 to 3 weeks.

Others followed with oral dosing.

Some studies also report improvement in:

clinical impairment scores
nerve conduction measures
multi-symptom neuropathy scales

A more recent randomised trial found that 600 mg oral ALA once daily for 12 weeks improved several neuropathy symptom measures in people already taking gabapentin or pregabalin.

That makes the evidence more relevant to real-world combination care.

Where the evidence is weaker

Chemotherapy-induced peripheral neuropathy

Evidence here is much thinner.

Results are mixed.

A lot of the enthusiasm comes from:

diabetic neuropathy trials
preclinical oxidative-stress models
mitochondrial-injury logic in chemotherapy-damaged nerves

That is useful context.

It is not the same as strong clinical proof in chemotherapy-induced neuropathy.

Metal-detox claims

ALA can bind metals in laboratory settings.

That does not mean neuropathy benefit in humans comes from clearing platinum or other metals out of nerves.

Human neuropathy studies mainly support antioxidant, mitochondrial, and circulation-related explanations.

Longer-term progression prevention

Some longer studies suggest stabilisation or partial benefit.

The signal is not consistent.

A 2024 Cochrane review concluded that ALA probably has little or no effect on neuropathy symptoms at six months compared with placebo.

That does not mean ALA never helps.

It means the benefit is not universal, and expectations should stay realistic.

Practical and safety notes

ALA should not be added quietly in the background during active cancer treatment.

Review it with the oncology team, pharmacist, and GP first.

Common practical points include:

neuropathy studies often use 600 mg per day
use is usually time-limited rather than open-ended
gastrointestinal side effects can include nausea or reflux
rash can occur
blood-sugar lowering can matter, especially in people already using glucose-lowering medication

Rare hypoglycaemia has been reported.

ALA may also interact with:

diabetes medications
thyroid medication
selected chemotherapy or targeted therapies

That interaction question matters more than many people expect.

Bottom line

ALA is a plausible adjunct for neuropathy support.

Its best evidence is in diabetic neuropathy, not chemotherapy-induced neuropathy.

For some people, it may help with pain, tingling, or numbness.

For others, it may do very little.

The most useful way to think about it is as one option inside a broader nerve-support plan, not as a stand-alone answer.

Key references

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.